Moderna Executive Says Expects To File For Approval Of RSV Vaccine For Adults Aged 18-59 In 2024
Portfolio Pulse from Benzinga Newsdesk
Moderna expects to file for approval of its RSV vaccine for adults aged 18-59 in 2024, as stated by a company executive at a Goldman Sachs conference.
June 10, 2024 | 5:51 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Goldman Sachs hosted the conference where Moderna announced its plans for the RSV vaccine approval, showcasing its role in facilitating important industry updates.
While Goldman Sachs hosted the conference, the direct impact on its stock price is minimal as the news primarily pertains to Moderna's product development.
CONFIDENCE 70
IMPORTANCE 30
RELEVANCE 20
POSITIVE IMPACT
Moderna plans to file for approval of its RSV vaccine for adults aged 18-59 in 2024, which could potentially expand its product portfolio and revenue streams.
The news indicates a potential new revenue stream for Moderna, which could positively impact its stock price in the short term as investors anticipate future growth.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100